Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy

Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy

Show other versions (1)

<jats:title>Abstract</jats:title><jats:p>Despite progress in the treatment of acute lymphoblastic leukemia (ALL), T-cell ALL (T-ALL) has limited treatment options, particularly in the setting of relapsed/refractory disease. Using an unbiased genome-scale CRISPR-Cas9 screen we sough...

Full description

Bibliographic Details
Main Authors: Pikman, Yana, Ocasio-Martinez, Nicole, Alexe, Gabriela, Dimitrov, Boris, Kitara, Samuel, Diehl, Frances F, Robichaud, Amanda L, Conway, Amy Saur, Ross, Linda, Su, Angela, Ling, Frank, Qi, Jun, Roti, Giovanni, Lewis, Caroline A, Puissant, Alexandre, Vander Heiden, Matthew G, Stegmaier, Kimberly
Format: Article
Language:English
Published: Springer Science and Business Media LLC 2021
Online Access:https://hdl.handle.net/1721.1/133547

Internet

https://hdl.handle.net/1721.1/133547

Similar Items